This unrestricted search can be problematic as search terms (such as mutation names) often have more than 1 meaning. For example, if a physician searches the clinical trials database for the EGFR mutation, which is a common cause of lung cancer, the search results will include clinical trials for the EGFR mutation mixed in with trials for eGFR, a drug to treat kidney disease.
A final example of search confusion occurs as clinical trials often exclude patients with certain mutations. For example, a text search for the KRAS mutation will retrieve "A Phase II Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases" 2 This study excludes patients with the KRAS mutation by including text in the clinical trial description that says "[patients are included which] . . . have a non-mutant (wild-type) K-ras gene." Although the clinical trial specifically excludes patients with the KRAS mutation, the ClinicalTrials.org search engine still retrieves the trial.
To remedy these search problems, the authors present a software system, CTMine, which begins with a list of common gene names (in this case, 6 genes). The system then collects clinical trials per gene/mutation by searching ClinicalTrials.gov. Occasionally, a search for a particular gene or mutation will retrieve a clinical trial which does not contain the appropriate text. As an additional verification step, the system uses regular expressions to verify that gene/mutation names correctly appear in the wording of each clinical trial retrieved by ClinicalTrials.org. The authors use Catalogue To further refine the search of clinical trials by mutation, the authors create a machine learning model to rule out clinical trials which are not pertinent to a search for cancer mutationfocused clinical trials (such as double use or in exclusion circumstances documented above). The authors created a training set of clinical trials, where oncologists judged the relevance of each trial. The authors created an online interactive software to streamline the judging process.
Finally, the authors create a cancer mutation-oriented interface ( Figure 1 ) which begins with a list of genes which the user can choose from and then allows the user to select the particular mutation related to the gene. The CTMine system only includes genes and mutations which appear in the clinical trials available to the system. The system allows oncologists to quickly search for clinical trials which focus on cancers with specific gene mutations, a function which is currently not available to the public.
Methods

Prior work
Clinical trial classification. This section focuses on systems which search or classify clinical trials using techniques drawn from natural language processing and machine learning. The accuracy of each system is given in Table 1 .
Bui et al 4 built a system (regular expression discovery [RED]) which uses a top-down approach involving both natural language processing and text matching to categorize smoking status and pain status data sets. The authors use the matching text common to a set of clinical trials to create regular expressions to use in search of new trials of the same type. They developed a new classifier called "novel regular expression classifier" (RED) and created 2 text classifiers based on RED. The accuracy and F score for the system are 83.0% and 85.7%, respectively.
Frenz 5 created a Perl Regular (PREP) which allows clinicians to search PubMed for clinical trials which focus on mutations that cause deafness. The system makes use of regular expressions. The system largely mirrors the procedures implemented by state-of-the-art information retrieval systems. Although this system uses regular expressions in their search, it does not check results for false-positive results, resulting in search terms with 2 meanings to "slip" through the system. The accuracy of the PREP system is 77%. Meric-Bernstam et al 6 match clinical trials to gene-level alterations by a combination of natural language processing of gene names and using therapeutics known a priori to target those genes. The authors hoped to automatically match patients with certain mutations to trials at MD Anderson Medical Center which focused on the same mutation. In final results, 28.4% of patients who matched with clinical trials went on to enroll in the proposed trials.
Clinical trial recommendation strategies. There are several studies which are not directly related to text search, but the work helps inform and augment current search strategies. Sarker et al 7 explore several machine learning algorithms such as Support Vector Machines (SVMs), Bayes Net, and K-Nearest Neighbors, among others, to predict the strength of evidence in clinical trials. The authors used the Strength of Recommendation Taxonomy grading criteria as classifier values. The machine learning models reported the highest F score as 68.2%. This work could be used to inform search recommendations based on the strength of evidence.
In the same vein, Kilicoglu et al 8 create an ensemble of supervised machine learners to leverage manually annotated MEDLINE citations and then proceed to find scientifically rigorous treatment-related studies. The machine learning techniques used were Naive Bayes, SVMs, and Boosting. The classifiers were trained on 10 000 manually annotated MEDLINE citations and tested on an additional 2000 citations. The machine learning models created did better than chance (F score of 66%).
System description
The CTMine system currently collects clinical trials for the following 6 genes: ALK, BRAF, EGFR, ERBB2, KIT, and KRAS. The system includes these genes because they are highly represented among patients with cancer, resulting in their inclusion in a significant number of clinical trials. A system diagram of the CTMine system is given in Figure 2 .
Clinical trial collection. A Web crawler was built in the Python programming language library to extract the list of mutations returned from the COSMIC search engine API (application programming interface) per gene. Catalogue of Somatic Mutations in Cancer is an online repository of all known cancer mutations for a particular gene. The repository also provides the identifiers of studies in which researchers study certain mutations.
After COSMIC was used to extract a list of mutations and alternate IDs for each gene, a single query was constructed per mutation and passed to ClinicalTrials.gov. Each constructed query was used to retrieve a list of clinical trials from ClinicalTrials.org. The text of each clinical trial was subsequently checked to ensure that the particular search mutation existed in the wording of each retrieved trial, which was not always guaranteed. Regular expressions used for mutation search are given in Table 2 . Note that regular expression 1 appears to subsume regular expression 2. However, the authors used regular expression 2 to match mutations and then retrieve the mutation number so that they could perform an additional check and ensure that the gene and mutation were in fact related.
In the next step, the system stores the text and title from each clinical trial along with a link to the relevant gene mutation in a PostgreSQL relational database. Per clinical trial, the system also stores additional metadata attributes. These include trial status, the phase of the trial, study type, and study condition.
As a working example, consider the ALK gene. The CTMine system would first collect the names of alternate IDs and mutation names related to ALK from COSMIC. The system would then generate a query for each mutation name and gene/alternate ID. One such clinical trial returned would be "Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations (STARTRK-1)" 9 which when using the regular expressions outlined in Table 2 which when checked does, in fact, contain the gene ALK. However, ClinicalTrials.gov also returns the clinical trial "A Long-Term Safety Study of ALKS 5461" 10 which does not reference the ALK gene but the drug ALKS 5461. The regular expressions below would not match in this case, and the system discards the clinical trial.
Clinical trial refinement methods. After collecting clinical trials, a second phase was established to exclude trials which exhibited characteristics such as the double use of gene names and exclusion of patients with certain gene mutations. To this end, the authors created a machine learning model that excluded clinical trials which were not relevant to the particular gene mutation of interest. To build the classifier, experts were needed to read each clinical trial and manually score if the trial was related to a specific gene. The authors developed a clinical trial voting application for this purpose. Four oncology residents from Johns Hopkins University to were recruited to score each trial.
Clinical trial grading online application. In total, 429 clinical trials, which reference 6 genes, were collected by the system. There was some overlap between genes as clinical trials occasionally reference more than 1 gene. A Web application was built using the Django Web framework in Python to facilitate voting. Per clinical trial, the system presents a study and a given mutation. The voter then scores if the particular study would be valuable to a patient with the given gene mutation. The voter selected from the following choices: (1) not useful, (2) unknown (if they are unsure), (3) useful but check (if they are slightly unsure but would like another oncologist to check on their answer), or (4) useful. Voters were given the following instructions via the grading Web site:
You are presented with text of a clinical trial (follow the link) AND a gene mutation. Your task is to decide if the clinical trial presented would be useful in regard to treating a patient with cancer that presents the gene mutation that we provide.
You will answer no (not useful), unknown (if you are not sure), yes but check (if you are almost sure but want another doctor to check your answer), or yes.
A screenshot of the voting application is given in Figure 3 .
Results
Classification
The four oncologists were unable to vote on all 429 studies due to time constraints. A breakdown of studies voted on per gene/choice and studies voted on per grader is given in Tables 3 and 4 .
Weka, 11 a commonly used machine learning package written in Java, was used to create a predictive model. The authors tested both the SVM and Naive Bayes classifiers. The features used to create the model were the text of the clinical study and the class was the vote given by most of the graders per study. All text was transformed into a feature vector (the bag-ofwords model). Table 5 provides a list of Weka parameters, with a description, which were used to transform the text into the bag of words.
The authors used 3 training sets for classification. The first training set consisted of studies scored by all 4 doctors (n = 427). The second training set consisted of studies graded by 3 or more doctors (n = 402). The third training set consisted of studies graded by 2 or more doctors (n = 166). In all the training Gandy et al 5 sets, the authors marked the class as the majority consensus with ties broken in the following order: yes, no, unknown, and yes but check. A further breakdown by percentage and number of word features is given in Table 6 .
The F scores for all studies, when classified with Naive Bayes, SVMs, and Random Forests, are given in Table 7 . All results were statistically significant at the P < .05 level when compared with chance. It is evident that as the number of studies graded increases, the F score decreases, thought the starkest contrast is between consensus data featuring 3 or more graders and 4 or more graders. The Naive Bayes model yielded the poorest results, whereas SVM results and Random Forest results are nearly identical. Table 8 gives results for the SVM classifier on data with 2 or more voter consensus. A Pearson correlation statistic was performed to evaluate the correlation between the F score per gene and the percentage of studies per gene. The R score was not significant (P > .05). However, there are significant differences between F score results (note the F score of 57.1 for KIT and 57.1 for ERBB2). It is currently unclear why the SVM classifier was able to correctly predict the validity of a study in relation to a gene and warrants further investigation. Figure 4A is a heat map of the Cohen interrater reliability between all 4 graders and all graded studies. Values on the upper triangle are the Cohen correlation coefficient, and the lower triangle reflects the number of studies reviewed by both graders. Values along the diagonal are the total number of studies reviewed by both graders. As evident in the figure, the interrater reliability between the 4 graders was low. Of the 4 graders, grader 3 had the highest average interrater reliability, thought it only ranged from 0.39 to 0.5. For further analysis, we assumed that grader 3 was the "gold standard" and calculated the interrater reliability of each grader and grader 3 for each gene (see Figure 4B ). However, in this case, the interrater reliability only slightly improved (ranging from 0.48 to 0.6).
It is noteworthy that the weak consensus described above still yields high classification results by the machine learning algorithm. It is likely that the accuracy of the algorithm could improve by providing more training data. The additional training data would make it easier to define concrete features of Cancer Informatics cancer trials that lead to an oncologist rejecting (or conversely accepting) a clinical trial. The authors assume that the low interrater agreement would resolve with more graders. Figure 4C is a plot of the width of an exact binomial 95% confidence interval for the probability of selecting a trial as a function of the number of graders. In this case, a sharp drop occurs in the curve, and then the curve starts to level out after approximately 50 graders. This curve exists even a mutation is erroneously associated with a trial at a probability of 50%.
Discussion
As this study seeks to improve the search functionality of the ClinicalTrials.gov system in relation to mutation-specific clinical trials, it is worthwhile to compare the functionality of both systems. Table 9 gives a point-by-point comparison of both systems.
As stated previously, an important feature of the CTMine system is its method of searching by regular expression. ClinicalTrials.gov does not have this functionality, and therefore, text search is limited. Also, CTMine only returns clinical trials that directly refer to cancer studies, whereas ClinicalTrials. gov also includes trials which mention medications that treat the side effects of chemotherapy drugs, as well as clinical trials for diseases other than cancer. Regarding "double use," several mutation names (such as EGFR) are also names of particular types of other diseases. The CTMine system detects and excludes most trials with these features from its search results.
Regarding search features of both systems, status, phase, type, and condition are search options available on both platforms. However, ClinicalTrials.gov also provides search functionality regarding interventions, outcomes, sponsors, location, sex, age, funder, safety, and data, whereas CTMine does not include these search parameters.
Future Work and Conclusions
In this article, the authors discuss difficulties that occur in mutation-specific search as a result of ClinicalTrials.org Web site's limited search functionality. The authors offer a solution in the form of the CTMine system. Results demonstrate that the CTMine system assigns articles to the associated gene with high accuracy (88%). The authors also demonstrate that CTMine has a fully functional workflow, beginning with article download and ending with an interactive Web application. 
